Healthcare Services

Rising Cancer Prevalence Driving Growth in Tumor Marker Testing Market

April 28, 2026April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Tumor Marker Testing Market Between 2026 And 2030?

The tumor marker testing market has shown considerable growth in recent years. This market is anticipated to expand from $18.6 billion in 2025 to $20.12 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.2%. The increase observed in the past can be ascribed to several factors, including the rising incidence of cancer, the more extensive application of laboratory diagnostics within oncology, the expansion of cancer testing services offered by hospitals, the presence of established biochemical markers, and the development of diagnostic laboratory networks.

The tumor marker testing market size is projected to experience substantial growth in the upcoming years. It is anticipated to reach $27.23 billion by 2030, at a compound annual growth rate (CAGR) of 7.9%. This growth throughout the forecast period can be attributed to an increasing demand for early cancer detection, the rising adoption of precision oncology methods, the expansion of companion diagnostics, the growing application of biomarkers in therapy selection, and ongoing advancements in cancer biomarker research. Major trends expected during the forecast period include the increasing adoption of multiplex tumor marker panels, the rising use of blood-based cancer diagnostics, the deeper integration of tumor markers in treatment monitoring, the wider expansion of early cancer screening programs, and an enhanced focus on personalized oncology care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20668&type=smp

Which Key Drivers Are Affecting The Tumor Marker Testing Market Development?

The growing incidence of cancer is anticipated to propel the expansion of the tumor marker testing market in the future. Cancer is a condition characterized by the unrestrained proliferation of abnormal cells within the body. These cells have the capacity to invade adjacent tissues and spread to other bodily regions through the bloodstream and lymphatic systems. The escalation in cancer rates is influenced by factors such as aging populations, increased environmental exposures, changes in lifestyle, and enhancements in detection and diagnosis. Tumor marker testing is employed to diagnose, monitor treatment efficacy, and detect recurrence in various cancers by measuring specific substances produced by cancer cells. For instance, in October 2025, according to the National Health Service, a Uk-based government agency, in 2023, there were 354,820 new cancer diagnoses, or 972 per day on average, 8,605 higher than in 2022. Thus, the increasing cancer prevalence is fostering the growth of the tumor marker testing market.

What Segment Categories Shape The Tumor Marker Testing Market Segment Landscape?

The tumor marker testing market covered in this report is segmented –

1) By Product: Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines

2) By Methods: Screening, Imaging, Theranostics, Other Methods

3) By Application: Hospitals, Commercial Or Private Laboratories, Physician Offices Or Group Practices, Cancer Clinics, Ambulatory Care Centers

Subsegments:

1) By Biochemical Markers: Alpha-fetoprotein (AFP), Prostate-Specific Antigen (PSA), Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA 125), Cancer Antigen 19-9 (CA 19-9), Human Chorionic Gonadotropin (hCG)

2) By Oncogenes: HER2 Or neu, KRAS, BRAF, EGFR (Epidermal Growth Factor Receptor), c-MYC, p53

3) By Growth Factors: Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-ß), Fibroblast Growth Factor (FGF), Insulin-like Growth Factor (IGF)

4) By Hormones: Estrogen Receptors (ER), Progesterone Receptors (PR), Thyroglobulin, Calcitonin, Adrenocorticotropic Hormone (ACTH), Gastrin

5) By Colony Stimulating Factors: Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Macrophage Colony-Stimulating Factor (M-CSF)

6) By Lymphokines: Interleukin-2 (IL-2), Interferon-gamma (IFN-?), Tumor Necrosis Factor-alpha (TNF-a), Interleukin-6 (IL-6)

What Trends Are Transforming The Tumor Marker Testing Market?

Entities engaged in the tumor marker testing market are increasingly prioritizing the development of advanced diagnostic tools, such as molecular testing solutions, to enhance their competitive standing. Molecular testing solutions refer to sophisticated diagnostic techniques that analyze genetic material (DNA or RNA) to identify mutations, pathogens, or specific biomarkers at a molecular level. As an illustration, in April 2024, RGCC International GmbH, a company based in Switzerland specializing in personalized cancer treatment, launched Onco-D-clare, a revolutionary cancer detection test. This innovative test empowers individuals to detect cancer prior to the onset of symptoms by combining molecular biology and artificial neural networks. Onco-D-clare operates by isolating peripheral blood mononuclear cells from blood samples, subsequently conducting a comprehensive analysis of gene expression across more than 90 genes.

Who Are The Companies Operating Across The Tumor Marker Testing Market Value Chain?

Major companies operating in the tumor marker testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Inc., Agilent Technologies Inc, Hologic Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., Myriad Genetics, Ortho Clinical Diagnostics PLC, Veracyte Inc., Biodesix Inc., Biocept Inc., Proteomedix AG, OncoCyte Corporation, Biocartis NV

Get The Full Tumor Marker Testing Market Report:

https://www.thebusinessresearchcompany.com/report/tumor-marker-testing-global-market-report

Which Region Represents The Largest Share Of The Tumor Marker Testing Market?

North America was the largest region in the tumor marker testing market in 2025. The regions covered in the tumor marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Tumor Marker Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/tumor-marker-testing-global-market-report

Browse Through More Reports Similar to the Global Tumor Marker Testing Market 2026, By The Business Research Company

Circulating Tumor Cells Market Report 2026

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Tumor Necrosis Factor Inhibitor Drugs Market Report

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Tumor Infiltrating Lymphocytes Market Report

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795